Physician profile

Merelyn Thomas

Shreveport, LA

NPI 1588308480

$139.63

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$122.60
Education$17.03

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Gilead Sciences, INC. $27.03 2023 Sunlenca
Aurinia Pharma U.S., INC. $22.04 2023 Lupkynis
Amgen INC. $20.18 2023 Tavneos
Mallinckrodt Hospital Products INC. $19.30 2024 Acthar
Astrazeneca Pharmaceuticals Lp $18.82 2024 Fasenra
Opko Pharmaceuticals, LLC $17.03 2024 Rayaldee
Merck Sharp & Dohme LLC $15.23 2023 Zerbaxa, Dificid, Recarbrio

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Merelyn Thomas

$139.63

in general payments reported 2019-2025

Years
2023-2024
Top company
Gilead Sciences, INC.

https://glasscript.com/doctor/11550876/merelyn-thomas

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.